Potentially Accelerating Transformative Medicines to Market

Guggenheim 3rd Annual Boston Healthcare Conference

Mikael Dolsten, M.D., Ph.D. President Worldwide R&D

December 15, 2015

2

Forward-looking Statements

• This presentation includes forward-looking statements about, among other things, development of Pfizer’s products and product candidates, including their potential benefits, expected market opportunity and expected regulatory submissions and approvals that are subject to substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Additional information regarding these factors can be found in Pfizer’s Annual Report on Form 10-K for the fiscal year ended December 31, 2014 and in our subsequent reports on Form 10-Q, including in the sections thereof captioned “Risk Factors” and “Forward-Looking Information and Factors That May Affect Future Results”, as well as in our subsequent reports on Form 8-K, all of which are filed with the SEC and available at www.sec.gov and www.pfizer.com. The forward-looking statements in this presentation speak only as of the original date of this presentation, and we undertake no obligation to update or revise any of these statements.

• These reports are available on our website at www.pfizer.com in the “Investors – SEC Filings” section.

3

Strong Track Record of Approvals Over the last 5 years >25 Phase 3 starts & >15 key approvals (10 NME’s)

4

Strong Track Record of Approvals Over the last 5 years >25 Phase 3 starts & >15 key approvals (10 NME’s)

A Pneumococcal Vaccine for All Age Groups CAPiTA adult approval

5

Strong Track Record of Approvals Over the last 5 years >25 Phase 3 starts & >15 key approvals (10 NME’s)

Approved 1L Adv. Breast Cancer (BC) + Letrozole (US) Recurrent Adv. BC submission with priority review (US)

Phase 3 Start in adjuvant early BC

6

Strong Track Record of Approvals Over the last 5 years >25 Phase 3 starts & >15 key approvals (10 NME’s)

Approved for adv. renal cell carcinoma (RCC) Ph 3. Study Adjuvant RCC

Ph. 1 Inlyta® + Keytruda® shows activity in naïve adv. RCC

7

Strong Track Record of Approvals Over the last 5 years >25 Phase 3 starts & >15 key approvals (10 NME’s)

Approved for ALK+ NSCLC ROS1+ NSCLC Submission with Priority Review (US)

ROS1+ NSCLC Breakthrough Designation

8

Strong Track Record of Approvals Over the last 5 years >25 Phase 3 starts & >15 key approvals (10 NME’s)

Approved for treatment of rheumatoid arthritis (RA) Ph. 3 studies Psoriatic Arthritis & Ulcerative Colitis

QD MR NDA Submission (US)

9

Strong Track Record of Approvals Over the last 5 years >25 Phase 3 starts & >15 key approvals (10 NME’s)

Approved for Prevention Atrial Fibrillation Approved for Treatment of DVT & PE

10

Robust Pipeline Positioned to Sustain Productivity

Pfizer Pipeline (As of October 27, 2015)

Phase 1 30

84 Total

214 Discovery Projects

Phase 2 20

Phase 3 26

Registration 8

Discovery Projects

~50% biologics, biosimilars and vaccines

Programs with Accelerated Regulatory Pathways

e.g., inotuzumab (ALL)

avelumab (MCC)

Xalkori® (ROS+ NSCLC)

3 Breakthrough

Therapy

6 Fast Track Designation

e.g., S.aureus Vaccine

C.difficile Vaccine

rivipansel (SCD)

Orphan Drug Designation

14 e.g., F9 Gene Therapy (Hemophilia B)

PDE10 (Huntington’s Disease)

lorlatinib (ALK+ NSCLC )

11

Delivering Novel & Differentiated Future Potential Products Potential for >20 Approvals 2016-20, incl. 7 NMEs

CVMed

Hyperlipidemia bococizumab (PCSK9)

mAb, Oral

Type 2 Diabetes SGLT2, Glucagon

Oncology

Hematological SMO AML

ADCs inotuzumab ALL

Immuno-Oncology

PD-L1/PD-1 4-1BB, OX40, IDO1, CAR-T,

IO Combos 4-1BB/rituxan FL

Ibrance®

Breast Cancer & Beyond

Targeted Therapy Lorlatinib NSCLC, Bi-Functional Abs

Vaccines

Neo. & Older Adults (CMV,RSV,GBS)

Cancer Vaccines Active immunotherapy

Nosocomial S.aureus

Neuroscience

Alzheimer’s GSM/BACE

Pain tanezumab

Parkinson’s Dopamine Modulation

Huntington's PDE10

Cross Domain AMPA

Inflammation & Immunology

Xeljanz ® LCM QD, RA BID

Immuno-kinases Selective JAK’s, IRAK4

Rare Disease

Growth Hormone LAGH - Ped/Adult

Hemophillia Gene Tx F9, TFPI

Sickle Cell rivipansel

Neuromuscular Myostatin DMD

Biosimilars

rituximab

bevacizumab

trastuzumab

adalimumab

infliximab

Xalkori® ROS+ NSCLC

Xeljanz® New Indications

UC, Psoriatic Arthritis

C difficile Dopamine, GDNF

rivipansel SC, PDE9

PTK7 / EFNA4

Type 1 Diabetes IL7R mAb

Majority of Current Portfolio with Leader-In-Class or Value-In-Class Potential

12

ONCOLOGY

Lung, PDAC, SCCHN, Melanoma PD-L1,41BB,OX40,CAR-T,Combos

Ibrance® Beyond Breast Ca. & Continued I/O Momentum

VACCINES

S.aureus C.difficile

Accelerating Nosocomial Vaccines to Market

NEUROSCIENCE

Dopamine Modulation tanezumab anti-NGF

Lead in Class Neuroscience Assets

INFLAMMATION & IMMUNOLOGY

Xeljanz® - QD MR, PsA, UC JAK1, JAK3, Tyk2/JAK1, IRAK4

Leading JAK Biology New Indications & MOAs

RARE DISEASE

rivipansel, PDE9 SCD FIX Gene Therapy, TFPI Hemophilia

Innovative Therapies in Hematological Diseases

CVMED

bococizumab (PCSK9) mAb, Oral

A Differentiated Franchise Approach to PCSK9

Delivering Novel & Differentiated Future Potential Products 6 Near-Term Growth Platforms with Potential for Significant Market Opportunity

Q&A